Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 5/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091834 | 0.86 | SLC1A2 (0.40) | MEN1KMT2ABLMARG1SLC1A2 | |
| Proline SCHEMBL4398037 | 0.85 | MEN1 (0.44) | MEN1KMT2ABLMARG1SLC1A2 | |
| Proline SCHEMBL1196246 | 0.85 | MEN1 (0.44) | MEN1KMT2ABLMARG1SLC1A2 | |
| Proline SCHEMBL28467818 | 0.85 | MEN1 (0.44) | MEN1KMT2ABLMARG1SLC1A2 | |
| SCHEMBL302682 | 0.85 | NOS2 (0.41) | NOS2NOS3NOS1 | |
| Proline SCHEMBL1820143 | 0.82 | MEN1 (0.52) | MEN1KMT2ABLMARG1SLC1A2 | |
| Proline SCHEMBL162687 | 0.82 | MEN1 (0.52) | MEN1KMT2ABLMARG1SLC1A2 | |
| SCHEMBL4398036 | 0.80 | MEN1 (0.35) | MEN1KMT2ABLMARG1SLC1A2 | |
| SCHEMBL13519375 | 0.77 | NOS2 (0.35) | ARG1NOS2NOS3NOS1ARG2 | |
| SCHEMBL6534977 | 0.76 | SLC1A2 (0.33) | MEN1KMT2ABLMARG1SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115317589-A | Prolyl hydroxylase inhibitors and uses thereof | 中国海洋大学 | 2022-11-11 | — | — | CN | claimed |
| WO-2024077483-A1 | OLIGOPEPTIDE AND USE AND COMPOSITION THEREOF | 佛教慈济医疗财团法人 | 2024-04-18 | — | — | WO | disclosed |
| CN-117736264-A | Oligopeptide and application and composition thereof | 佛教慈济医疗财团法人 | 2024-03-22 | — | — | CN | disclosed |
| EP-3687564-B1 | RECOMBINANT COLLAGEN AND ELASTIN MOLECULES AND USES THEREOF | GELTOR INC (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023194333-A1 | RECOMBINANT SPIDER SILK-REINFORCED COLLAGEN PROTEINS PRODUCED IN PLANTS AND THE USE THEREOF | SWIFTPHARMA BV (BE) | 2023-10-12 | — | — | WO | disclosed |
| CN-116178525-A | Recombinant collagen and elastin molecules and uses thereof | 格尔托公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-110128502-B | Amphiphilic polypeptide molecule with temperature-sensitive aggregation-induced emission characteristic and preparation method thereof | 上海大学 | 2023-05-16 | — | — | CN | disclosed |
| US-20230104758-A1 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | ETH ZURICH (CH) | 2023-04-06 | — | — | US | disclosed |
| CN-111417404-B | Recombinant collagen and elastin molecules and uses thereof | 格尔托公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-115317589-A | Prolyl hydroxylase inhibitors and uses thereof | 中国海洋大学 | 2022-11-11 | — | — | CN | disclosed |
| US-8575311-B2 | Collagen peptide conjugates and uses therefor | PURDUE RESEARCH FOUNDATION (US) | 2013-11-05 | — | — | US | disclosed |
| WO-2012112767-A2 | COLLAGEN-TARGETED NANOPARTICLES | PURDUE RESEARCH FOUNDATION (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20110081324-A1 | COLLAGEN PEPTIDE CONJUGATES AND USES THEREFOR | PURDUE RESEARCH FOUNDATION (US) | 2011-04-07 | — | — | US | disclosed |
| EP-2300033-A1 | COLLAGEN PEPTIDE CONJUGATES AND USES THEREFOR | Purdue Research Foundation (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009140573-A1 | COLLAGEN PEPTIDE CONJUGATES AND USES THEREFOR | PURDUE RESEARCH FOUNDATION (US) | 2009-11-19 | — | — | WO | disclosed |
| EP-1996013-A2 | METHODS AND COMPOSITIONS FOR ORGAN AND TISSUE FUNCTIONALITY | Dask Technologies, LLC (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1940424-A2 | COMPOSITIONS AND METHODS FOR THE AUGMENTATION AND REPAIR OF DEFECTS IN TISSUE | Dask Technologies, LLC (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007035843-A2 | METHODS AND COMPOSITIONS FOR ORGAN AND TISSUE FUNCTIONALITY | DASK TECHNOLOGIES, LLC (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035363-A2 | COMPOSITIONS AND METHODS FOR THE AUGMENTATION AND REPAIR OF DEFECTS IN TISSUE | DASK TECHNOLOGIES, LLC (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070065415-A1 | Compositions and methods for the augmentation and repair of defects in tissue | DASK TECHNOLOGIES, LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104758-A1 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | DAO, LOX, AOC2 | MEN1 1331/4885KMT2A 773/4885BLM 2191/4885 |
| US-20110081324-A1 | COLLAGEN PEPTIDE CONJUGATES AND USES THEREFOR | COL14A1, COL1A1, COL2A1 | MEN1 3734/4885KMT2A 4319/4885BLM 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.